Association between BNT162b2 vaccination and health-related quality of life up to 18 months post-SARS-CoV-2 infection in Israel.

Association between BNT162b2 vaccination and health-related quality of life up to 18 months post-SARS-CoV-2 infection in Israel.

Publication date: Sep 22, 2023

We determined whether COVID-19 vaccination was associated with Quality of Life (QoL) changes among individuals previously infected with SARS-CoV-2 in Israel. Using a validated questionnaire, we collected information about socio-demographics, SARS-CoV-2 infection, COVID-19 vaccination and QoL (using the EQ-5D-5L tool) 3-18 months post-infection among adults tested for SARS-CoV-2 by polymerase chain reaction in Northern Israel between March 2020-June 2022. We compared post-COVID QoL between those vaccinated against COVID-19 at the time of infection and those not, using an adjusted linear regression model, stratified by time elapsed since infection. Of 951 participants, mean EQ-5D Utility Index (EQ-5D UI) was 0. 82 (SD = 0. 26) and 0. 83 (SD = 0. 25) among the 227 double and 250 triple vaccinated respectively, compared to 0. 76 (SD = 0. 33) among those who received 0 dose (n = 243). The size of the effect of vaccination was small (Cohen’s d = 0. 2). In the adjusted model, previously infected individuals vaccinated with two or more doses reported a QoL score post- infection 0. 05 points higher (CI = 0. 01-0. 10, p = 0. 02) compared with those unvaccinated when infected. No association between vaccination and QoL was detected beyond 12 months post-infection. Vaccination with two or more doses of COVID19 vaccine, or at least the BNT162b2 vaccine, may modestly mitigate QoL losses associated with post-acute COVID-19 symptoms, at least in the first 12 months post-infection.

Open Access PDF

Concepts Keywords
Bnt162b2 18months
Israel 5d
June Bnt162b2
Vaccinated Compared


Type Source Name
disease VO vaccination
disease IDO quality
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
disease VO vaccinated
disease VO time
disease VO dose
disease VO unvaccinated
disease VO vaccine
drug DRUGBANK Coenzyme M
disease MESH sequelae
disease MESH Long COVID
disease VO organization
disease IDO history
disease VO organ
disease MESH Chronic conditions
disease MESH hypertension
disease MESH Parkinson’s disease
disease MESH syndrome
disease MESH viral infections
disease MESH Middle East Respiratory Syndrome
disease MESH Severe Acute Respiratory Syndrome
disease VO effectiveness
disease VO population
disease VO Gap
disease MESH marital status
disease IDO symptom
drug DRUGBANK Pentaerythritol tetranitrate
disease VO vaccine dose
disease MESH COPD
disease MESH Asthma
pathway KEGG Asthma
drug DRUGBANK Silver
disease MESH clinical relevance
disease IDO acute infection
disease MESH acute disease
disease VO vaccine effectiveness
disease MESH reinfection
disease IDO country
disease VO USA
drug DRUGBANK Sodium lauryl sulfate
disease MESH education level
drug DRUGBANK Ranitidine
disease VO report
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease VO company

Original Article

(Visited 1 times, 1 visits today)